PT  - JOURNAL ARTICLE
AU  - Santini-Oliveira, Marilia
AU  - Pinto, Patrícia Machado
AU  - dos Santos, Tatiane
AU  - Vilar, Monica Magno
AU  - Grinsztejn, Beatriz
AU  - Veloso, Valdilea
AU  - Paes-de-Almeida, Elan C.
AU  - Amaral, Maria A. Z.
AU  - Ramos, Celso R.
AU  - Marroquin-Quelopana, Miryam
AU  - Coler, Rhea
AU  - Reed, Steven
AU  - Ciol, Marcia
AU  - Savino, Wilson
AU  - de Carvalho Parra, Juçara
AU  - dos Santos Almeida, Marília Sirianni
AU  - Tendler, Miriam
TI  - Development of the Sm14/GLA-SE - schistosomiasis vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial targeting healthy young women
AID  - 10.1101/2022.08.17.22278904
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.17.22278904
4099  - http://medrxiv.org/content/early/2022/08/19/2022.08.17.22278904.short
4100  - http://medrxiv.org/content/early/2022/08/19/2022.08.17.22278904.full
AB  - We report the successful closure of Phase I clinical trials of the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE) vaccine candidate against human Schistosomiasis, comprising Phases Ia and Ib. Shown here are the results of Phase Ib, an open, not placebo-controlled, standardized-dose immunization trial, involving 10 healthy 18-49 years old women submitted to the same clinical protocol and the same batch of cGMP Sm14+GLA-SE used in Phase Ia, which was one on men. Fifty µg Sm14 protein plus 10 µg GLA-SE per dose were given intramuscularly thrice at 30-day intervals. Participants were assessed clinically, biochemically, and immunologically for up to 120 days. In preambular experiments involving vaccinated pregnant female rabbits, we did not find any toxicological feature either in offspring or mothers, as ascertained by histopathology and biochemical parameters. The vaccine induced adaptive immunity in the animals, as defined by the detection of anti-Sm14 antibodies in the sera. In women, neither serious nor light adverse events were observed. Sm14+GLA-SE vaccination induced high titers of anti-Sm14 serum IgG antibody production. Total anti-IgG serum levels remained high 120 days after the first vaccination dose. Significant increases in Sm14-specific total IgG, IgG1, and IgG3 were observed 30 days after the first vaccination, with specific IgG2 and IgG4 after 60 days. Sm14+GLA-SE vaccination also elicited robust cytokine responses with increased TNFα, IFNγ, and IL-2 profiles in all female vaccinees on days 90 and 120.As in Phase Ia, the Sm14+GLA-SE vaccine was shown to be strongly immunogenic and well tolerated. The completion of Phase I clinical trials performed to the highest standards set by the Good Clinical Research Practice (GCP) standards and pre-clinical data in pregnant rabbits enabled the vaccine candidate to proceed to Phase II clinical trials in endemic areas.Study registration ID NCT01154049 at http://www.clinicaltrials.gov. Brazilian Registry of Clinical Trials UTN: U1111-1135-6815Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT01154049Funding StatementThis study was funded by FINEP (Governmental Funding Agency) grant no. 01.06.105800 FAPERJ (Rio de Janeiro State Funding Agency) grant no. E-26/010.001533/2014 IOC/FIOCRUZ (Oswaldo Cruz Institute/Oswaldo Cruz Foundation, Brazilian Ministry of Health) and OUROFINO Agronegócio, SP, Brazil, a 100% Brazilian company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for the Phase Ib trial was approved by Anvisa (CE# 0577594139) and by the Evandro Chagas Review Council of the National Institute of Infectious Diseases (INI), Fiocruz (CAAE 09627212.4.0000-5262)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll related data are included in the manuscript or in the supplementary files.